Until recently, the treatment of HER2-positive breast cancer was a serious burden on healthcare budgets due to the high cost of one of the basic drugs used in this condition - trastuzumab. Now, thanks to the introduction of biosimilar products, this cost has significantly decreased. This gives hope for expanding the reimbursement criteria for such treatment by the payer and extending it to a wider population of patients. Similar opportunities arise for patients with HER2-positive stomach cancer.

To ensure the proper quality of service provided to doctors by pharmaceutical companies producing biosimilar products, data on the perception of such products by oncologists are needed. Therefore, we invite you to participate in the nationwide research program entitled "Review of therapeutic behavior after the introduction of biosimilar trastuzumab HERZUMA to the market," which aims to obtain the aforementioned data.

Thanks to the collected information, it will be possible to better understand your needs, doubts, and convictions related to the use of biosimilar products in the treatment of breast and stomach cancer. This allows for adjusting the information provided about these drugs.